Who is sponsoring NCT05832320?

NCT05832320 is sponsored by Peking University People's Hospital.

What condition does NCT05832320 study?

NCT05832320 studies Acute Promyelocytic Leukemia, Induction Therapy, Oral.

What drugs are being tested in NCT05832320?

Interventions: Etoposide, Daunorubicin.

What is the status of NCT05832320?

NCT05832320 is currently RECRUITING.

Last reviewed 2024-05-10 · How we verify

Optimum Induction Therapy of Low-risk APL

NCT05832320 NA RECRUITING

Despite the high cure probability for acute promyelocytic leukemia (APL), a minority of patients will relapse and the risk factors for relapse are unclear. The goal of this clinical trial is to compare the effectiveness and safety of induction of oral all-trans retinoic acid (ATRA) and realgar-indigo naturalis formula (RIF) combined with oral etoposide or daunorubicin as cytoreductive therapies in low-risk APL. The present study was to explored a cytoreduction of an oral etoposide for low-risk APL with dual induction of ATRA and RIF as a high efficacy, low recurrence, and more convenient all-oral regimen.

Details

Lead sponsor	Peking University People's Hospital
Phase	NA
Status	RECRUITING
Enrolment	74
Start date	Sun Jan 01 2023 00:00:00 GMT+0000 (Coordinated Universal Time)
Completion	Tue Dec 31 2024 00:00:00 GMT+0000 (Coordinated Universal Time)

Conditions

Acute Promyelocytic Leukemia
Induction Therapy
Oral

Interventions

Etoposide
Daunorubicin

Countries

China